Q2 26 EPS
$-0.94
BEAT +20.59%
Est. $-1.18
Q2 26 Revenue
$10.2M
BEAT +37.03%
Est. $7.4M
Did CRSP Beat Earnings? Q2 2026 Results
CRISPR Therapeutics delivered a notably stronger-than-expected second quarter, posting an adjusted loss of $0.94 per share against a consensus estimate of $1.18, a beat of 20.59%, while revenue of $10.18 million cleared the $7.43 million estimate by … Read more CRISPR Therapeutics delivered a notably stronger-than-expected second quarter, posting an adjusted loss of $0.94 per share against a consensus estimate of $1.18, a beat of 20.59%, while revenue of $10.18 million cleared the $7.43 million estimate by 37.03% and reflected a 1,041.4% increase from the year-ago period. The primary driver was the emergence of $10.00 million in collaboration revenue, tied to accelerating commercial momentum behind CASGEVY, the gene-editing therapy co-developed with Vertex, which generated $76.00 million in partner-reported revenue during the quarter, representing 151% year-over-year growth. The net loss narrowed sharply to $91.15 million from $208.55 million a year prior, aided by a steep reduction in acquired in-process R&D expenses. The company's cash position stood at $2.36 billion as of June 30, 2026, bolstered by a convertible notes offering earlier this year. Morgan Stanley has recently lifted its price target on the stock, citing the CASGEVY label expansion to patients as young as two and upcoming pipeline readouts, including CTX310 durability data and zugo-cel autoimmune updates, as key catalysts heading into the second half of 2026.
Key Takeaways
- • CASGEVY revenue grew 151% year-over-year and 78% quarter-over-quarter to $76 million
- • FDA approval of CASGEVY for children as young as 2 years old expanded eligible patient population by approximately 5,500
- • Net loss narrowed significantly due to lower acquired in-process R&D expenses and growing CASGEVY revenue share
- • German reimbursement secured for CASGEVY for eligible patients 12 years and older
CRSP Forward Guidance & Outlook
CRISPR Therapeutics expects multiple milestones in the second half of 2026, including: a CTX310 Phase 1b clinical update and ESC Congress presentation of durability data (August 28, 2026); CTX611 Phase 2 update in total knee arthroplasty; further zugo-cel autoimmune and immuno-oncology clinical updates; an Lp(a) program (CTX321) update; nomination of up to two additional siRNA targets; and continued expansion of CASGEVY commercial access through regulatory submissions and reimbursement efforts globally, including pediatric submissions in Saudi Arabia and the UK.
CRSP YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
CRSP Revenue by Segment
With YoY comparisons, source: SEC Filings
“The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform. CASGEVY's momentum continued to build, highlighted by the FDA's approval for children as young as 2 years old, while we expanded our in vivo pipeline with the initiation of Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. We enter the second half of 2026 well positioned, with a number of important milestones ahead across our pipeline.”
— Samarth Kulkarni, Q2 2026 Earnings Press Release
CRSP Earnings Trends
CRSP vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CRSP EPS Trend
Earnings per share: estimate vs actual
CRSP Revenue Trend
Quarterly revenue: estimate vs actual
CRSP Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-1.18 | $-0.94 | +20.59% | $10.2M | +37.03% |
| Q1 26 MISS | $-1.23 | $-1.28 | -3.68% | $1.5M | -65.73% |
| Q4 25 MISS FY | $-1.23 | $-1.37 | -11.67% | $864,000 | -78.51% |
| FY Full Year | $-6.17 | $-6.47 | -4.91% | $3.5M | -42.66% |
| Q3 25 BEAT | $-1.29 | $-1.17 | +9.23% | $889,000 | -90.07% |
| Q2 25 MISS | $-1.40 | $-2.40 | -71.55% | $892,000 | -86.15% |
| Q1 25 MISS | $-1.28 | $-1.58 | -23.75% | $865,000 | -85.50% |